We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Agilent Technologies (A - Free Report) ten years ago? It may not have been easy to hold on to A for all that time, but if you did, how much would your investment be worth today?
Agilent Technologies' Business In-Depth
With that in mind, let's take a look at Agilent Technologies' main business drivers.
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets.
Over the last three years, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences and Diagnostics Markets (LDG), Agilent CrossLab (ACG) and Applied Markets (AMG).
The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce, as necessary.
Agilent reported revenues of $6.95 billion in fiscal 2025. The company generated 40.4% of revenues from the Americas, 27.7% from Europe, and 31.9% from the Asia-Pacific region in fiscal 2025.
LDG accounted for 39.2% of fiscal 2025 revenues, AMG contributed 18.9%, and ACG represented the remaining 41.8%.
Most of the competition for these three segments comes from Bruker Corp., Danaher Corp, Affymetrix, GE Healthcare, Life Technologies Corp., Thermo Fisher Scientific, Waters Corp., Illumina, Inc., Abbott Laboratories, Sakura, Roche, Perkin Elmer Corp., Shimadzu Corp, Heidenhain Corp., Malvern Instruments, Seiko Instruments, Veeco Instruments and Zygo Corp.
In first-quarter fiscal 2024, Agilent announced a change in its operating segments to move cell analysis business from life sciences and applied markets segment to its diagnostics and genomics operating segment. The new structure includes the Life Sciences and Diagnostics Markets Group (LDG), Applied Markets Group (AMG) and Agilent Cross Lab Group (ACG).
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Agilent Technologies, ten years ago, you're likely feeling pretty good about your investment today.
A $1000 investment made in September 2016 would be worth $3,583.89, or a 258.39% gain, as of September 23, 2026, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
The S&P 500 rose 256.64% and the price of gold increased 213.61% over the same time frame in comparison.
Going forward, analysts are expecting more upside for A.
Agilent's fiscal 2026 execution is supported by sustained instrument replacement demand, resilient pharma exposure, expanding specialty CDMO activity, and recurring consumables and service pull-through. Recent product launches and the completed Biocare acquisition broaden its workflow reach, while Ignite continues to lift operating efficiency. Management's higher full-year outlook reinforces confidence that these drivers can carry into year-end, with fourth-quarter targets implying growth. Offsetting this, demand remains uneven in parts of academia, government and Europe, while China has shown sharp quarter-to-quarter variability. Acquisition financing has also increased debt, although cash generation and net leverage remain manageable.
The stock has jumped 8.07% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 7 higher, for fiscal 2026; the consensus estimate has moved up as well.
View the Zacks #1 Rank List
Image: Bigstock
If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Agilent Technologies (A - Free Report) ten years ago? It may not have been easy to hold on to A for all that time, but if you did, how much would your investment be worth today?
Agilent Technologies' Business In-Depth
With that in mind, let's take a look at Agilent Technologies' main business drivers.
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets.
Over the last three years, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences and Diagnostics Markets (LDG), Agilent CrossLab (ACG) and Applied Markets (AMG).
The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce, as necessary.
Agilent reported revenues of $6.95 billion in fiscal 2025. The company generated 40.4% of revenues from the Americas, 27.7% from Europe, and 31.9% from the Asia-Pacific region in fiscal 2025.
LDG accounted for 39.2% of fiscal 2025 revenues, AMG contributed 18.9%, and ACG represented the remaining 41.8%.
Most of the competition for these three segments comes from Bruker Corp., Danaher Corp, Affymetrix, GE Healthcare, Life Technologies Corp., Thermo Fisher Scientific, Waters Corp., Illumina, Inc., Abbott Laboratories, Sakura, Roche, Perkin Elmer Corp., Shimadzu Corp, Heidenhain Corp., Malvern Instruments, Seiko Instruments, Veeco Instruments and Zygo Corp.
In first-quarter fiscal 2024, Agilent announced a change in its operating segments to move cell analysis business from life sciences and applied markets segment to its diagnostics and genomics operating segment. The new structure includes the Life Sciences and Diagnostics Markets Group (LDG), Applied Markets Group (AMG) and Agilent Cross Lab Group (ACG).
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Agilent Technologies, ten years ago, you're likely feeling pretty good about your investment today.
A $1000 investment made in September 2016 would be worth $3,583.89, or a 258.39% gain, as of September 23, 2026, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
The S&P 500 rose 256.64% and the price of gold increased 213.61% over the same time frame in comparison.
Going forward, analysts are expecting more upside for A.
Agilent's fiscal 2026 execution is supported by sustained instrument replacement demand, resilient pharma exposure, expanding specialty CDMO activity, and recurring consumables and service pull-through. Recent product launches and the completed Biocare acquisition broaden its workflow reach, while Ignite continues to lift operating efficiency. Management's higher full-year outlook reinforces confidence that these drivers can carry into year-end, with fourth-quarter targets implying growth. Offsetting this, demand remains uneven in parts of academia, government and Europe, while China has shown sharp quarter-to-quarter variability. Acquisition financing has also increased debt, although cash generation and net leverage remain manageable.
The stock has jumped 8.07% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 7 higher, for fiscal 2026; the consensus estimate has moved up as well.